[1]朱婷婷,王权,刘勇,等.伴浆液性视网膜脱离的糖尿病囊样黄斑水肿的危险因素及康柏西普治疗效果研究[J].眼科新进展,2019,39(4):350-353.[doi:10.13389/j.cnki.rao.2019.0079]
　ZHU Ting-Ting,WANG Quan,LIU Yong,et al.Conbercept treats diabetic cystoids macular edema with serous retinal detachment and its risk factors[J].Recent Advances in Ophthalmology,2019,39(4):350-353.[doi:10.13389/j.cnki.rao.2019.0079]
点击复制

伴浆液性视网膜脱离的糖尿病囊样黄斑水肿的危险因素及康柏西普治疗效果研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年4期
页码:
350-353
栏目:
应用研究
出版日期:
2019-04-05

文章信息/Info

Title:
Conbercept treats diabetic cystoids macular edema with serous retinal detachment and its risk factors
作者:
朱婷婷; 王权; 刘勇; 陈威; 赵燕燕; 王华; 接传红; 田天; 姜彩辉
100142　北京市，空军特色医学中心眼科 （朱婷婷，王权，刘勇，陈威，赵燕燕，王华，姜彩辉）；100142　北京市，安徽医科大学空军临床学院（朱婷婷，姜彩辉）；100142　北京市，中国中医科学院眼科医院（接传红，田天）
Author(s):
ZHU Ting-Ting; WANG Quan; LIU Yong; CHEN Wei; ZHAO Yan-Yan; WANG Hua; JIE Chuan-Hong; TIAN Tian; JIANG Cai-Hui
Department of Ophthalmology，Air Force General Hospital （ZHU Ting-Ting，WANG Quan，LIU Yong，CHEN Wei，ZHAO Yan-Yan，WANG Hua，JIANG Cai-Hui），Beijing 100142，China；Anhui Medical University Air Force Clinical College （ZHU Ting-Ting，JIANG Cai-Hui），Beijing 100142，China；Eye Hospital，China Academy of Chinese Medical Sciences （JIE Chuan-Hong，TIAN Tian），Beijing 100142，China
关键词:
糖尿病黄斑水肿; 囊样黄斑水肿; 视网膜脱离; 光学相干断层扫描; 血管生成抑制剂
Keywords:
diabetic macular edema; cystoid macular edema; retinal detachment; optical coherence tomography; angiogenesis inhibitors
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2019.0079
文献标志码:
A
摘要:
目的　探讨伴浆液性视网膜脱离（serous retinal detachment，SRD）的糖尿病囊样黄斑水肿（cystoid macular edema，CME）和不伴SRD的糖尿病CME形成的影响因素及康柏西普治疗疗效的差异。方法　选取就诊于空军特色医学中心并行康柏西普治疗的50例（70眼）糖尿病CME患者纳入研究，其中28例42眼为不伴SRD的CME水肿类型，为单纯CME组；22例28眼为伴SRD的CME水肿类型，为伴SRD组。比较可能影响两种CME形成的全身指标（血压、血糖、血脂等）和眼部情况，包括糖尿病视网膜病变分期，基线黄斑中心凹厚度（central macular thickness，CMT）等；并比较两组DME患者接受单纯康柏西普治疗后的疗效差异。结果　单因素分析显示，单纯CME组水肿类型的发生与高脂蛋白a水平、增生型糖尿病视网膜病变（proliferative diabetic retinopathy，PDR）、既往全视网膜光凝史和既往黄斑光凝史均相关（均为P＜0.05）。伴SRD组水肿类型的发生与高尿酸水平、高胆固醇水平和高基线CMT均相关（均为P＜0.05）；多因素Logistic回归分析显示，较高基线CMT为伴SRD组水肿类型发生的独立危险因素［OR（95% CI）=1.006（1.002~1.010）］。两种类型的CME患者接受康柏西普治疗后明显有效（均为P＜0.000 1），伴SRD的CME水肿消退较不伴SRD的CME效果更好（P＜0.05），但术后视力比较，差异无统计学意义（P＞0.05）。结论　较高尿酸和总胆固醇水平与SRD的发生有关，基线CMT较高是伴SRD的CME发生的独立危险因素；高脂蛋白a水平、PDR、既往全视网膜光凝史和既往黄斑光凝史与不伴SRD的CME发生有关。伴SRD的CME接受康柏西普治疗的效果较不伴SRD的CME效果更好，SRD可能是DME抗血管内皮生长因子治疗预后良好的指标。
Abstract:
Objective　To investigate the factors in diabetic cystoid macular edema （CME） with and without serous retinal detachment （SRD），and to compare the patients’ outcome after Conbercept therapy.Methods　A retrospective consecutive case series study of 50 diabetic CME patients （70 eyes） treated with Conbercept therapy in Air Force Medical Center was conducted，including 28 diabetic CME patients （42 eyes） as CME without SRD type （simple CME group），while the other 22 diabetic CME patients （28 eyes） as CME with SRD type （CME with SRD group）.The biochemical markers（blood pressure，blood glucose，serum lipids）and eye conditions，such as diabetic retinopathy stages and baseline central macular thickness （CMT） were compared，and their outcome after Conbercept treatment was recorded and compared.Results　The univariate analysis showed that high lipoprotein a （pro-a） levels，proliferative diabetic retinopathy （PDR），panretinal photocoagulation （PRP） and macular photocoagulation were associated with simple CME （all P<0.05），while high uric acid （UA），high total cholesterol （TC） levels，and high baseline CMT were associated with CME with SRD （all P<0.05）.From multiple regression analysis，high baseline CMT was positively associated with CME with SRD group［OR（95%CI）=1.006（1.002-1.010）］.Both types of diabetic CME outcome after Conbercept were significantly effective （both P<0.000 1），There was no difference in visual outcome between the two groups （P＞0.05），but the CME with SRD type has a better anatomy outcome （P<0.05）.Conclusion　High UA and high TC levels are associated with the occurrence of diabetic CME with SRD type.High baseline CMT is an independent risk factor for CME with SRD type；pro-a，PDR，previous PRP and previous macular photocoagulation are associated with simple CME type.The outcome of anti-VEGF treatment in CME with SRD type is better than that of CME without SRD type，SRD maybe an indicator of good prognosis of anti-VEGF therapy.

参考文献/References:

［1］　KLEIN R，KNUDTSON M D，LEE K E，GANGNON R，KLEIN B E.The Wisconsin epidemiologic study of diabetic retinopathy：XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes［J］.Ophthalmology，2008，115（11）：1859-1868.
［2］　LANG G E，LANG S J.Clinical treatment of diabetic macular edema［J］.Klin Monbl Augenheilkd，2011，228（1）：R1-11.
［3］　OTANI T，KISHI S，MARUYAMA Y.Patterns of diabetic macular edema with optical coherence tomography［J］.Am J Ophthalmol，1999，127（4）：688-693.
［4］　MITCHELL P，BANDELLO F，SCHMIDT-ERFURTH U，LANG G E，MASSIN P，SCHLINGEMANN R O，et al.RESTORE STUDY GROUP.The RESTORE study：ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema［J］.Ophthalmology，2011，118（4）：615-625.
［5］　GUNGEL H，ALTAN C.The relationship between fundus fluorescein angiographic findings and serous macular detachment in diabetic macular edema［J］.Retina，2013，33（9）：1895-1901.
［6］　GHOSH S，BANSAL P，SHEJAO H，HEGDE R，ROY D，BISWAS S.Correlation of morphological pattern of optical coherence tomography in diabetic macular edema with systemic risk factors in middle aged males［J］.Int Ophthalmol，2015，35（1）：3-10.
［7］　SHIMURA M，YASUDA K，YASUDA M，NAKAZAWA T.Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema［J］.Retina，2013，33（4）：740-747.
［8］　HONG T T，LIU G F，GAO X X，FAN Y，WANG J.Short-term outcomes of intravitreal injection of conbercept for diabetic macular edema and restoration of ellipsoid zone［J］.Rec Adv Ophthalmol，2017，37（11）：1053-1056.
洪婷婷，刘广峰，高新晓，范颖，汪军.糖尿病黄斑水肿玻璃体内注射康柏西普的短期疗效和椭圆体带完整性改变的观察［J］.眼科新进展，2017，37（11）：1053-1056.
［9］　OZTURK B T，KERIMOGLU H，ADAM M，GUNDUZ K，OKUDAN S.Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema［J］.J Diabetes Complications，2011，25（5）：298-302.
［10］　ETDR S.Early photocoagulation for diabetic retinopathy.Early treatment diabetic retinopathy study report number9［J］.Ophthalmology，1991，98：766-785.
［11］　XIE X W，XU L，JONAS J B，WANG Y X.Prevalence of diabetes among subjects with known diabetes in China：the Beijing Eye study［J］.Eur J Ophthalmol，2009，19（1）：91-99.
［12］　YAU J W，ROGERS S L，KAWASAKI R，LAMOUREUX E L，KOWALSKI J W，BEK T，et al.Global prevalence and major risk factors of diabetic retinopathy［J］.Diabetes Care，2012，35（3）：556-564.
［13］　ZHANG X，BAO S，LAI D，RAPKINS R W，GILLIES M S.Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas［J］.Diabetes，2008，57（4）：1026-1033.
［14］　CAMPOCHIARO P A.Molecular pathogenesis of retinal and choroidal vascular diseases［J］.Prog Retin Eye Res，2015，49（1）：67-81.
［15］　OHNO S，KOHJITANI A，MIYATA M，TOHYA A，YAMASHITA K，HASHIGUCHI T，et al.Recovery of endothelial function after minor-to-moderate surgery is impaired by diabetes mellitus，obesity，hyperuricemia and sevoflurane-based anesthesia［J］.Int Heart J，2018，59（3）：559-565.
［16］　PUDDU P，PUDDU G M，CRAVERO E，VIZIOLI L，MUSCARI A.Relationships among hyperuricemia，endothelial dysfunction and cardiovascular disease：Molecular mechanisms and clinical implications［J］.J Cardiol，2012，59（3）：235-242.
［17］　SOPHIE R，LU N，CAMPOCHIARO P A.Predictors of functional and anatomic outcomes in patients with diabetic Macular edema treated with ranibizumab［J］.Ophthalmology，2015，122（7）：1395-1401.
［18］　KOYTAK A，ALTINISIK M，SOGUTLU SARI E，ARTUNAY O，UMURHANAKKAN J C，TUNCER K.Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema［J］.Eye（Lond），2013，27（6）：716-721.

相似文献/References:

[1]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[2]沈强 张学东.糖尿病黄斑水肿的发病机制及治疗进展[J].眼科新进展,2012,32(2):000.
[3]赵勇 张卯年 任兵.激素缓释系统治疗糖尿病黄斑水肿新进展[J].眼科新进展,2012,32(10):000.
[4]曹薇 崔红平 张美萍.23G微切口玻璃体切割手术治疗糖尿病视网膜病变[J].眼科新进展,2013,33(11):000.
[5]刘斌,杨玉霞,刘杏,等.玻璃体内注射Lucentis治疗糖尿病黄斑水肿[J].眼科新进展,2015,35(1):045.[doi:10.13389/j.cnki.rao.2015.0013]
　LIU Bin,YANG Yu-Xia,LIU Xing,et al.Intravitreal injection of Lucentis for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):045.[doi:10.13389/j.cnki.rao.2015.0013]
[6]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):246.[doi:10.13389/j.cnki.rao.2015.0066]
[7]徐浩,白宁艳,吕鹏,等. 雷珠单抗玻璃体内注射与黄斑部格栅样光凝联合治疗糖尿病性黄斑水肿的疗效观察[J].眼科新进展,2015,35(8):781.[doi:10.13389/j.cnki.rao.2015.0215]
　XU Hao,BAI Ning-Yan,LV Peng,et al. Intravitreous injection of ranibizumab combined with macular grid photocoagulation for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):781.[doi:10.13389/j.cnki.rao.2015.0215]
[8]董秀清,冯松福,柯晓云.应用光学相干断层扫描量化评估糖尿病黄斑水肿的临床研究[J].眼科新进展,2017,37(2):133.[doi:10.13389/j.cnki.rao.2017.0035]
　DONG Xiu-Qing,FENG Song-Fu,KE Xiao-Yun.Evaluating diabetic macular edema quantificationally by optical coherence tomography[J].Recent Advances in Ophthalmology,2017,37(4):133.[doi:10.13389/j.cnki.rao.2017.0035]
[9]莫香红,黄敏丽.糖尿病黄斑水肿的激光治疗进展[J].眼科新进展,2017,37(7):688.[doi:10.13389/j.cnki.rao.2017.0175]
　MO Xiang-Hong,HUANG Min-Li.Laser treatment progress for diabetic macular edema[J].Recent Advances in Ophthalmology,2017,37(4):688.[doi:10.13389/j.cnki.rao.2017.0175]
[10]朱婷婷,王权,姜彩辉.糖尿病黄斑水肿治疗新进展[J].眼科新进展,2019,39(3):296.[doi:10.13389/j.cnki.rao.2019.0067]
　ZHU Ting-Ting,WANG Quan,JIANG Cai-Hui.Recent research advances in the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(4):296.[doi:10.13389/j.cnki.rao.2019.0067]

备注/Memo

备注/Memo:
首都卫生发展科研专项重点攻关项目（编号：2016-1-4181）；中国中医科学院自主选题（编号：ZZ0808008）
更新日期/Last Update: 2019-04-15